0001572426-16-000189.txt : 20160701
0001572426-16-000189.hdr.sgml : 20160701
20160701195826
ACCESSION NUMBER: 0001572426-16-000189
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160701
FILED AS OF DATE: 20160701
DATE AS OF CHANGE: 20160701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farrell Geraldine T
CENTRAL INDEX KEY: 0001632385
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 161747881
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2016-07-01
0001618561
Nexvet Biopharma plc
NVET
0001632385
Farrell Geraldine T
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE
L2
R35 FR98
IRELAND
0
1
0
0
VP Operations, General Counsel
Ordinary Shares
2016-07-01
4
M
0
2867.00
.125
A
24120.00
I
By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Famil A/C>
Ordinary Shares
2016-07-01
4
M
0
2340.00
.125
A
6640
D
Options to Purchase Shares
.125
2016-07-01
4
M
0
2867.00
0.00
D
2019-07-01
Ordinary Shares
2867.00
2866.00
I
By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>
Restricted Share Units
.125
2016-07-01
4
M
0
2340.00
0.00
D
2020-07-01
Ordinary Shares
2340.00
7018.00
D
The reporting person and her spouse have shared voting and dispositive power with respect to these reported securities.
The remaining 2,866 options will vest and become exercisable on 7/1/17.
2,340 of the Restricted Share Units shall vest and become convertible on 7/1/17 and 2,339 of the Restricted Share Units shall vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
/s/ Geraldine T. Farrell
2016-07-01